Skip to main content

Table 5 Comparison of treatment outcome between groups 1 and 2

From: Volumetric magnetic resonance-guided high-intensity focused ultrasound ablation of uterine fibroids through abdominal scars: the impact of a scar patch on therapeutic efficacy and adverse effects

Treatment outcome All patients Group 1 Group 2 P value
Patients 63 17 46  
 Fibroid volumea
  Baseline 171.7 ± 149.3 (6.0–794.0) 179.4 ± 176.1 (37.0–794.0) 168.9 ± 140.2 (6.0–637.0) 0.806
  6 months 92.4 ± 93.4 (4.0–578.0) 87.8 ± 68.6 (11.0–295.0) 94.1 ± 101.6 (4.0–578.0) 0.813
  Reduction ratio (6 months) 0.44 ± 0.22 (−0.21–0.84) 0.45 ± 0.27 (−0.03–0.80) 0.43 ± 0.21 (−0.21–0.84) 0.747
 Symptom severity scoreb
  Baseline 53.5 ± 16.5 (21.9–93.8) 55.0 ± 15.9 (31.2–87.5) 53.0 ± 16.5 (21.9–93.8) 0.672
  6 months 13.0 ± 19.8 (0.0–100.0) 16.5 ± 21.9 (0.0–62.5) 11.7 ± 19.0 (0.0–100.0) 0.391
  Improvement ratio (6 months) 0.77 ± 0.31 (−0.2–1.0) 0.7 ± 0.39 (−0.2–1.0) 0.79 ± 0.28 (−0.07–1.0) 0.055
  1. Values in parentheses represent ranges
  2. aLargest treated fibroid only
  3. bTransformed symptom severe score (SSS) can range from 0 to 100